Paricalcitol for reduction of albuminuria in diabetes
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2011-02, Vol.377 (9766), p.636-636 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 636 |
|---|---|
| container_issue | 9766 |
| container_start_page | 636 |
| container_title | The Lancet (British edition) |
| container_volume | 377 |
| creator | Fourtounas, Costas |
| description | |
| doi_str_mv | 10.1016/S0140-6736(11)60225-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_853225189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0140673611602250</els_id><sourcerecordid>853225189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-d245823425ee32e5aeed11866adadb07936641bce11b574ad86b5474cf4c65a93</originalsourceid><addsrcrecordid>eNqFkMtKxDAUQIMoOj4-QelOXVRz82rdKCK-QFBQwV1Ik1uIdhpNWmH-3nZmnIUbV9mce27uIWQf6AlQUKfPFATNVcHVEcCxoozJnK6RCYhC5FIUb-tkskK2yHZK75RSoajcJFsMOBeSFRMin0z01jTWd6HJ6hCziK63nQ9tFurMNFU_9W0fvcl8mzlvKuww7ZKN2jQJ95bvDnm9uX65ussfHm_vry4fciuU6nLHhCwZF0wicobSIDqAUinjjKtoccaVElBZBKhkIYwrVTV8XdhaWCXNGd8hhwvvZwxfPaZOT32y2DSmxdAnXUo-3A3lSMoFaWNIKWKtP6OfmjjTQPUYTM-D6bGGBtDzYJoOcwfLDX01Rbea-i00ABcLAIc7vz1GnazH1qLzEW2nXfD_rjj_Y7CNb8foHzjD9B762A4RNejENF1IRgfA3ED5DwBRjj4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853225189</pqid></control><display><type>article</type><title>Paricalcitol for reduction of albuminuria in diabetes</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Fourtounas, Costas</creator><creatorcontrib>Fourtounas, Costas</creatorcontrib><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(11)60225-0</identifier><identifier>PMID: 21334527</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Albuminuria - blood ; Albuminuria - drug therapy ; Bone Density Conservation Agents - adverse effects ; Bone Density Conservation Agents - therapeutic use ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - drug therapy ; Ergocalciferols - adverse effects ; Ergocalciferols - therapeutic use ; Humans ; Internal Medicine ; Long-Term Care ; Phosphorus - blood ; Prognosis ; Randomized Controlled Trials as Topic</subject><ispartof>The Lancet (British edition), 2011-02, Vol.377 (9766), p.636-636</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-d245823425ee32e5aeed11866adadb07936641bce11b574ad86b5474cf4c65a93</citedby><cites>FETCH-LOGICAL-c466t-d245823425ee32e5aeed11866adadb07936641bce11b574ad86b5474cf4c65a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(11)60225-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64387</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21334527$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fourtounas, Costas</creatorcontrib><title>Paricalcitol for reduction of albuminuria in diabetes</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><subject>Albuminuria - blood</subject><subject>Albuminuria - drug therapy</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Ergocalciferols - adverse effects</subject><subject>Ergocalciferols - therapeutic use</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Long-Term Care</subject><subject>Phosphorus - blood</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKxDAUQIMoOj4-QelOXVRz82rdKCK-QFBQwV1Ik1uIdhpNWmH-3nZmnIUbV9mce27uIWQf6AlQUKfPFATNVcHVEcCxoozJnK6RCYhC5FIUb-tkskK2yHZK75RSoajcJFsMOBeSFRMin0z01jTWd6HJ6hCziK63nQ9tFurMNFU_9W0fvcl8mzlvKuww7ZKN2jQJ95bvDnm9uX65ussfHm_vry4fciuU6nLHhCwZF0wicobSIDqAUinjjKtoccaVElBZBKhkIYwrVTV8XdhaWCXNGd8hhwvvZwxfPaZOT32y2DSmxdAnXUo-3A3lSMoFaWNIKWKtP6OfmjjTQPUYTM-D6bGGBtDzYJoOcwfLDX01Rbea-i00ABcLAIc7vz1GnazH1qLzEW2nXfD_rjj_Y7CNb8foHzjD9B762A4RNejENF1IRgfA3ED5DwBRjj4</recordid><startdate>20110219</startdate><enddate>20110219</enddate><creator>Fourtounas, Costas</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110219</creationdate><title>Paricalcitol for reduction of albuminuria in diabetes</title><author>Fourtounas, Costas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-d245823425ee32e5aeed11866adadb07936641bce11b574ad86b5474cf4c65a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Albuminuria - blood</topic><topic>Albuminuria - drug therapy</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Ergocalciferols - adverse effects</topic><topic>Ergocalciferols - therapeutic use</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Long-Term Care</topic><topic>Phosphorus - blood</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fourtounas, Costas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fourtounas, Costas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paricalcitol for reduction of albuminuria in diabetes</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2011-02-19</date><risdate>2011</risdate><volume>377</volume><issue>9766</issue><spage>636</spage><epage>636</epage><pages>636-636</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21334527</pmid><doi>10.1016/S0140-6736(11)60225-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2011-02, Vol.377 (9766), p.636-636 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_853225189 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Albuminuria - blood Albuminuria - drug therapy Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Diabetic Nephropathies - blood Diabetic Nephropathies - drug therapy Ergocalciferols - adverse effects Ergocalciferols - therapeutic use Humans Internal Medicine Long-Term Care Phosphorus - blood Prognosis Randomized Controlled Trials as Topic |
| title | Paricalcitol for reduction of albuminuria in diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T06%3A32%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paricalcitol%20for%20reduction%20of%20albuminuria%20in%20diabetes&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Fourtounas,%20Costas&rft.date=2011-02-19&rft.volume=377&rft.issue=9766&rft.spage=636&rft.epage=636&rft.pages=636-636&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(11)60225-0&rft_dat=%3Cproquest_cross%3E853225189%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853225189&rft_id=info:pmid/21334527&rft_els_id=1_s2_0_S0140673611602250&rfr_iscdi=true |